2-(S)-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid | 1206475-68-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(S)-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid
• 英文别名: p-SCN-Bn-nota；2-[(5S)-4,7-bis(carboxymethyl)-5-[(4-isothiocyanatophenyl)methyl]-1,4,7-triazonan-1-yl]acetic acid
• CAS: 1206475-68-4
• 化学式: C₂₀H₂₆N₄O₆S
• 分子量: 450.516
• InChiKey: ABEIJMWLNYUWMD-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.5
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  166
• 氢给体数：
  3
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2-(S)-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid 、 N,N'-(6-(6-aminohexylamino)-6-oxohexane-1,5-diyl)bis(3-maleimido-propanamide) 在 三乙胺 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以28%的产率得到(S)-2-(2-{4-[3-(6-{2,6-bis[3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)propanamido]-hexanamido}-hexyl)thiourea]benzyl}-4,7-bis(carboxymethyl)-1,4,7-triazacylononane)acetic acid
  参考文献：
  名称：

  马来酰亚胺功能化的 NOTA 衍生物作为用于位点特异性放射性标记的双功能螯合剂。

  摘要：

  描述了带有 1,4,7-三氮杂环壬烷-N,N',N''-三乙酸 (NOTA) 螯合剂的单和双马来酰亚胺作为新型双功能螯合剂的两种基本和简单的合成路线。该合成方法的特点是简单、反应时间短，以及实用的纯化方法和可接受的非常好的化学产率。这两种合成途径的有用性通过一组单马来酰亚胺和双马来酰亚胺官能化的 NOTA 衍生物的制备得到了证明。总之，这两种方法可以很容易地扩展到进一步定制的马来酰亚胺-NOTA 螯合剂的合成，以用于各种应用。

  DOI：

  10.3390/molecules16065228

文献信息

• Imaging compounds, methods of making imaging compounds, methods of imaging, therapeutic compounds, methods of making therapeutic compounds, and methods of therapy
  申请人：Chen Xiaoyuan

  公开号：US20080267882A1

  公开（公告）日：2008-10-30

  Embodiments of the present disclosure provide for RGD compounds that include a multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide, methods of making the RGD compound, pharmaceutical compositions including RGD compound, methods of using the RGD compositions or the pharmaceutical compositions including RGD compositions, methods of diagnosing and/or targeting angiogenesis related disease and related biological events, kits for diagnosing and/or targeting angiogenesis related disease and related biological events, and the like. In addition, the present disclosure includes compositions used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging) of the RGD compounds in vivo.

  本公开的实施例提供了包括多聚体RGD（精氨酸-甘氨酸-天冬氨酸（Arg-Gly-Asp））肽的RGD化合物，制备RGD化合物的方法，包括RGD化合物的药物组合物，使用RGD组合物或包括RGD组合物的药物组合物的方法，诊断和/或靶向血管生成相关疾病和相关生物事件的方法，用于诊断和/或靶向血管生成相关疾病和相关生物事件的试剂盒等。此外，本公开还包括用于体内非侵入性成像（例如正电子发射断层扫描（PET）成像）的RGD化合物的成分和方法。
• [EN] RADIOLIGANDS FOR PRETARGETED PET IMAGING AND METHODS OF THEIR THERAPEUTIC USE<br/>[FR] RADIOLIGANDS POUR L'IMAGERIE TEP PRÉCIBLÉE ET MÉTHODES POUR LEUR UTILISATION THÉRAPEUTIQUE
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：WO2016182804A1

  公开（公告）日：2016-11-17

  Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.

  本文描述了使用Al[18F]-NOTA标记的四氮唑放射配体进行Tz/TCO基于预靶向策略。与其他成像策略相比，这种成像策略使得癌症在较早的时间点能够被清晰地描绘出来，并且与直接标记抗体相比，进一步降低了对健康组织的辐射剂量。基于Al的小分子18F成像，如四氮唑，以前尚未实现，因为在放射氟化过程中四氮唑会分解。相比其他放射标记方法，放射氟化具有优势，因为除了半衰期较短外，18F更容易获得并因此更容易融入医院工作流程中。
• [EN] CHELATED PSMA INHIBITORS<br/>[FR] INHIBITEURS CHÉLATÉS DU PSMA
  申请人：CANCER TARGETED TECHNOLOGY LLC

  公开号：WO2012174136A1

  公开（公告）日：2012-12-20

  Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

  本文定义的化合物可用于：（1）用于检测和/或鉴定表达PSMA的细胞的诊断方法；（2）包含本发明化合物的与药用稀释剂一起的组合物；以及（3）用于成像前列腺癌细胞的方法。
• RADIOLABELED BBN-RGD HETERODIMERS FOR CANCER TARGETING
  申请人：LI ZIBO

  公开号：US20100015058A1

  公开（公告）日：2010-01-21

  The present disclosure encompasses heterodimeric compositions for delivering radiolabeled and other ligands to a cell or tissue, and particularly to compositions and methods of use thereof for targeting and imaging cells and tissues expressing both an integrin and gastrin-releasing peptide receptor, in particular prostate cancer cells. The disclosure, therefore, firstly encompasses compositions that can comprise a heterodimeric probe comprising a first peptide domain comprising a moiety capable of selectively binding to an integrin; a second peptide domain comprising a moiety capable of selectively binding to a gastrin-releasing peptide receptor; a linker connecting the first peptide domain and the second peptide domain; and a prosthetic group. The first peptide domain comprises at least one tripeptide comprising the amino acid sequence of arginine-glycine-aspartate, and the second domain can be the peptide bombesin(7-14). The prosthetic group can be the fluoride isotope 18 F so that the heterodimeric probe may be detected by positron emission tomography or by single photon emission computed tomography, or a metal radionuclide. The radionuclide may be attached to the probe via a chelating tether.

  本公开涵盖了用于将放射性标记和其他配体传递到细胞或组织的异源二聚体组合物，特别是用于定位和成像表达整合素和胃泌素释放肽受体的细胞和组织的组合物及其使用方法。因此，首先涵盖了可以包括异源二聚体探针的组合物，该异源二聚体探针包括第一肽结构域，其中包括能够选择性结合整合素的结构域；第二肽结构域，其中包括能够选择性结合胃泌素释放肽受体的结构域；连接第一肽结构域和第二肽结构域的连接物；以及一个假体基团。第一肽结构域包括至少一个三肽，其氨基酸序列为精氨酸-甘氨酸-天冬氨酸，第二结构域可以是肽骨胃素(7-14)。假体基团可以是氟同位素18F，以便通过正电子发射断层扫描或单光子发射计算机断层扫描，或金属放射性同位素来检测异源二聚体探针。放射性同位素可以通过螯合连接物连接到探针上。
• COMPOSITIONS AND METHODS FOR MEASURING OXIDATIVE STRESS
  申请人：Washington University

  公开号：US20210386874A1

  公开（公告）日：2021-12-16

  The present disclosure provides for imaging agents and methods of making and using the same. The imaging agent comprises a luminol component comprising a luminol moiety or functional analogue thereof; a chelator; a linker group bonding or complexing the luminol component to the chelator; and a radiolabel component bound to the chelator. The imaging agent described herein is capable of monitoring, targeting, or imaging oxidative stress, reactive oxygen species (ROS), superoxide generation, or hydrogen peroxide generation, mediating pathophysiology of different disease states.

  本公开提供了成像剂及其制备和使用的方法。该成像剂包括一种亮氨酮组分，包括亮氨酮基团或其功能类似物；螯合剂；将亮氨酮组分与螯合剂结合或络合的连接器基团；以及结合到螯合剂上的放射性标记组分。本文所描述的成像剂能够监测、定位或成像氧化应激、反应性氧化物种（ROS）、超氧离子生成或过氧化氢生成，介导不同疾病状态的病理生理学。